DGAP-News: Cytos Biotechnology AG: The Journal of Allergy and Clinical Immunology publishes phase 2a study results with Cytos Biotechnology's CYT003 for the treatment of allergic asthma.
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Study
Cytos Biotechnology AG: The Journal of Allergy and Clinical Immunology
publishes phase 2a study results with Cytos Biotechnology's CYT003 for
the treatment of allergic asthma.
13.03.2013 / 07:00
---------------------------------------------------------------------
The Journal of Allergy and Clinical Immunology publishes phase 2a study
results with Cytos Biotechnology's CYT003 for the treatment of allergic
asthma.
Schlieren (Zurich), Switzerland, March 13, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) today announced the publication of the results from its phase 2a
clinical trial with CYT003-QbG10 (CYT003), a first-in-class immune
modulator in clinical development as a potential new treatment for allergic
asthma. The data are published in the March issue of The Journal of Allergy
and Clinical Immunology (JACI) in the article entitled 'The novel TLR-9
agonist QbG10 shows clinical efficacy in persistent allergic asthma' by
Kai-Michael Beeh, MD, et al. (J Allergy Clin Immunol. 2013
Mar;131(3):866-74).
The article was selected for comment by the JACI Editors ('The Editors'
Choice') under the heading 'Get the balance right - therapeutic immune
modulation in patients with allergic asthma' (J Allergy Clin Immunol. 2013
Mar; 131 (3):683).
The published study is a randomized, double-blind, placebo-controlled trial
in patients with persistent allergic asthma requiring long-term treatment
with inhaled corticosteroids (ICS). The study took place at five centers in
Germany and recruited 63 patients who received 7 weekly to bi-weekly
subcutaneous injections, with efficacy assessment during 12 weeks. ICS
treatment was withdrawn in two steps from 100% to 50% to 0%. Clinical
endpoints included asthma control determined by a validated questionnaire
(ACQ), lung function objectively assessed by spirometry (FEV1), day and
night-time asthma symptoms and use of relief medication. In addition
inflammatory markers (exhaled nitric oxide and eosinophils in the
peripheral blood) were evaluated. The study met all clinical endpoints. In
patients treated with CYT003 their asthma control improved despite ICS
withdrawal. In patients on placebo, the withdrawal of ICS, as expected, led
to a worsening of the disease with a statistically significant and
clinically important difference between treatment groups. Treatment with
CYT003 was safe and generally well tolerated.
About CYT003
Cytos' lead candidate CYT003 is a first-in-class immune modulator in
clinical development as a potential new treatment for allergic asthma.
CYT003 is currently being evaluated in a global, randomized and
placebo-controlled Phase 2b clinical trial as an add-on therapy in 360
patients with moderate to severe allergic asthma not sufficiently
controlled on standard controller therapy. The study was initiated in Q4
2012 and top-line results are expected in H1 2014.
Cytos has completed a Phase 2a study demonstrating CYT003 maintains asthma
control and lung function, despite standard inhaled corticosteroid
withdrawal. Its attractive safety profile is further supported by a
database of over 450 patients treated with CYT003 in previous studies.
CYT003 acts via a novel mechanism of action to selectively suppress the
body's immune response to allergens, whichis considered a predominant risk
factor for asthma.
About allergic asthma
Asthma is one of the most common chronic diseases, with an estimated 300
million individuals affected worldwide. Its prevalence is increasing,
especially among children, with an expected 400 million patients by 2025.
Allergic asthma is the most common type of asthma with 75%-85% patients
testing positive for allergies.
Asthma is a chronic inflammatory disorder of the airways. Chronically
inflamed airways are hyper-responsive; they become obstructed and airflow
is limited (by bronchoconstriction, mucus plugs, and increased
inflammation) when airways are exposed to various risk factors. Common
triggers include exposure to allergens (e.g. house dust mites, animal fur,
pollens and molds), smoke, chemical fumes, respiratory (viral) infections,
exercise, strong emotional expressions, chemical irritants, and drugs (such
as aspirin and beta blockers). Symptoms include recurring episodes of
wheezing, breathlessness, chest tightness, and coughing, particularly at
night or in the early morning.
###
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten(at)cytos.com
US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
e-mail: susan(at)sanoonan.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
first-in-class biologic in Phase 2 clinical development as a potential new
treatment for allergic asthma.
CYT003 acts via a novel, allergen-independent mechanism of action to
selectively suppress the body's immune response to allergens, a predominant
risk factor for asthma. In a successfully completed Phase 2a study, CYT003
was shown to maintain asthma control and lung function and asthma control
in patients with persistent allergic asthma, even as standard inhaled
corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in
over 450 patients to date.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
www.cytos.com
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.
End of Corporate News
---------------------------------------------------------------------
13.03.2013 This press release was distributed by EQS CORPORATE
COMMUNICATIONS.
www.eqs.com - news archive: www.eqs.com/ch/presskit
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
SwitzerlandPhone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Frankfurt in Open Market ; SIX
End of News EquityStory AG News-Service
---------------------------------------------------------------------
203712 13.03.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.03.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 238789
Anzahl Zeichen: 25398
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 282 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology AG: The Journal of Allergy and Clinical Immunology publishes phase 2a study results with Cytos Biotechnology's CYT003 for the treatment of allergic asthma."
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
